IPN10200 + IPN10200 dose A + IPN10200 dose B
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine, Chronic Migraine
Trial Timeline
Oct 10, 2024 → Jun 15, 2027
NCT ID
NCT06625060About IPN10200 + IPN10200 dose A + IPN10200 dose B
IPN10200 + IPN10200 dose A + IPN10200 dose B is a phase 2 stage product being developed by Ipsen for Episodic Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06625060. Target conditions include Episodic Migraine, Chronic Migraine.
What happened to similar drugs?
3 of 16 similar drugs in Episodic Migraine were approved
Approved (3) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06625060 | Phase 2 | Recruiting |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 44 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| BOTOX + Placebo | AbbVie | Phase 3 | 32 |
| Atogepant 60 mg | AbbVie | Phase 3 | 40 |
| Atogepant + Ubrogepant | AbbVie | Approved | 43 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 47 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 43 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 40 |
| Erenumab | Novartis | Phase 3 | 40 |
| Placebo + AMG 301 | Amgen | Phase 2 | 35 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 29 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 41 |
| Methylprednisolone | Brain Biotech | Approved | 33 |